Therachon evolves to a multi-asset rare disease company

10.10.2018 16:32

Related tags

intestine

Therachon has acquired GLyPharma Therapeutic Inc. adding apraglutide to its portfolio. Apraglutide targets short bowel syndrome (SBS) and other devastating rare gastrointestinal diseases. The transaction comes on the heels of a $60 million mezzanine financing led by Novo Holdings.

Under the agreement, Therachon has acquired the exclusive development and commercialization rights to apraglutide, originally discovered by Ferring Pharmaceuticals and exclusively licensed to GLyPharma in 2012. Apraglutide is a next-generation, synthetic GLP-2 analog that has undergone extensive preclinical characterization and optimization. It has successfully completed a Phase 1 single ascending dose/multiple ascending dose trials in healthy volunteers demonstrating a superior pharmacokinetic (PK) profile that affords an easy to use, once-weekly dosing regimen and is currently being investigated in two Phase 2 studies in short bowel syndrome.

An estimated 20,000-40,000 patients are thought to suffer from SBS in the US and Europe. Intestinal failure is a common and debilitating consequence of SBS. It is a life-threatening complication characterized by malabsorption and malnutrition, infections, blood clots and poor quality of life.

“Expanding our pipeline with this new asset supports our mission of harnessing internal and external scientific innovation to make a difference in the lives of people living with serious rare conditions,” said Luca Santarelli, M.D., chief executive officer at Therachon. “Like achondroplasia, our other area of focus, people living with SBS have significant unmet medical needs. We believe apraglutide offers a potential best-in-class profile for efficacy, as well as a favorable dosing regimen and improved tolerability compared with other GLP-2 analogs.”

“This is an exciting time for Therachon as we continue to identify and advance best-in-disease therapies for  rare conditions with significant unmet medical need through both internal R&D and selected acquisitions,” said Behrad Derakhshan, Ph.D., head of business development.

(Press release)

Picture: T. L. Furrer - fotolia.com

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Principal

19.10.2018
Editorial

More openness to disruptive ideas

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS

In order to provide the best quality for you, our system uses "cookies", which are stored on your device. Cookies are necessary to identify what information (job advertisement, questionnaire, etc) you have already seen. IP address is used for the same purposes as described above.

When creating a profile, applying to the newsletter, job subscriptions and etc, you agree that the data, which you have entered, will be stored and processed in the system in order to provide services, which you have applied for.

We do NOT sell your personal data to any 3rd party services.

You must be 18 or older years old to use our services. If you are underage, you must have a permission to use our services from your parent or guardian. It is necessary in order to store and process your data.

By continuing to use our services, you agree with the these terms. You can withdraw your agreement at any time, by deleting cookies from your device and by sending request for deleting your data to the administrator.